MicroRNA‐193a‐5p exerts a tumor suppressor role in glioblastoma via modulating NOVA1
Background and Objectives Glioblastoma (GBM) is the most common and lethal of intracranial tumors, which is characterized by extensive proliferation and the diffused invasion of tumor cells. MicroRNA‐193a‐5p (miR‐193a‐5p) have been demonstrated previously as a functional suppressor in the developmen...
Gespeichert in:
Veröffentlicht in: | Journal of cellular biochemistry 2019-04, Vol.120 (4), p.6188-6197 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Background and Objectives
Glioblastoma (GBM) is the most common and lethal of intracranial tumors, which is characterized by extensive proliferation and the diffused invasion of tumor cells. MicroRNA‐193a‐5p (miR‐193a‐5p) have been demonstrated previously as a functional suppressor in the development and progression of various cancers. The current study aimed to investigate whether miR‐193a‐5p influences cell proliferation and migration through the mitogen‐activated protein kinase/extracellular signal‐regulated kinase signaling pathway by targeting neuro‐oncological ventral antigen 1 (NOVA1) in glioblastoma.
Materials and Methods
The miR‐193a‐5p expression was detected by quantitative real‐time polymerase chain reaction assay in GBM tissues and cell lines. Cell Counting Kit‐8 assay, colony formation analysis, wound‐healing, and transwell invasion assays were performed to evaluate cell proliferation, colony formation, migration, and invasion, respectively. Western blot analysis and luciferase reporter gene assay were performed to verify the downstream target gene of miR‐193a‐5p.
Results
The expression of miR‐193a‐5p was significantly downregulated in GBM tissues and cell lines. Kaplan‐Meier analysis showed that patients with low miR‐193a‐5p expression had a shorter disease‐free survival (P |
---|---|
ISSN: | 0730-2312 1097-4644 |
DOI: | 10.1002/jcb.27906 |